

CUMBERLAND PHARMACEUTICALS INC

Form 8-K

August 01, 2017

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of  
Report  
(Date of  
Earliest  
Event  
Reported):  
August 1,  
2017 (July  
31, 2017)

Cumberland Pharmaceuticals Inc.

---

(Exact name of registrant as specified in its charter)

Tennessee

(State or other jurisdiction of incorporation)

001-33637

(Commission File  
Number)

62-1765329

(I.R.S. Employer Identification  
No.)

2525 West End Avenue, Suite 950, Nashville,  
Tennessee

(Address of principal executive offices)

37203

(Zip Code)

Registrant's telephone number, including area code: (615) 255-0068

Not Applicable

---

Former name or former address, if changed since last report

Edgar Filing: CUMBERLAND PHARMACEUTICALS INC - Form 8-K

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01 Other Events

On July 31, 2017, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing the Company began distributing dexrazoxane, sold under the brand name Totect®, to U.S. wholesalers. Totect is an FDA-approved emergency oncology intervention indicated to treat the toxic effects of anthracycline chemotherapy in case of extravasation. Extravasation occurs when an injected medicine escapes from the blood vessels and circulates into surrounding tissues in the body, causing severe damage and serious complications. Totect can limit such damage without the need for additional surgeries and procedures and enable patients to continue their essential anti-cancer treatment.

A copy of the press release is furnished as Exhibit 99.1.

---

## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Cumberland Pharmaceuticals Inc.

August 1, 2017 By: Michael Bonner

Name: Michael Bonner

Title: Chief Financial Officer

---

## Exhibit Index

Exhibit No.	Description
-------------	-------------

99.1	Press release dated July 31, 2017
------	-----------------------------------